Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Boehringer Ingelheim
Express Scripts

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Sacubitril

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Sacubitril: Sponsors, patents, clinical trial progress

Sacubitril is an investigational drug.

There have been 48 clinical trials for Sacubitril. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2016.

The most common disease conditions in clinical trials are Heart Failure, Hypertension, and Diabetes Mellitus. The leading clinical trial sponsors are Novartis Pharmaceuticals, Brigham and Women's Hospital, and National Heart Centre Singapore.

There are forty-two US patents protecting this investigational drug and four hundred and seventy-four international patents.

Recent Clinical Trials for Sacubitril
Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCCNovartis PharmaceuticalsPhase 4
Sacubitril/Valsartan in Left Ventricular Assist Device RecipientsUniversity of ZagrebPhase 4
The Effects of Natriuretic Peptide Augmentation on Cardiometabolic Health in African AmericansUniversity of Alabama at BirminghamPhase 2

See all Sacubitril clinical trials

Clinical Trial Summary for Sacubitril

Top disease conditions for Sacubitril
Top clinical trial sponsors for Sacubitril

See all Sacubitril clinical trials

US Patents for Sacubitril

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sacubitril   See Pricing Organic compounds INTRA-CELLULAR THERAPIES, INC. (New York, NY)   See Pricing
Sacubitril   See Pricing Synthetic linear apelin mimetics for the treatment of heart failure NOVARTIS AG (Basel, CH)   See Pricing
Sacubitril   See Pricing Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sacubitril

Drugname Country Document Number Estimated Expiration Related US Patent
Sacubitril World Intellectual Property Organization (WIPO) 2016022836 2034-08-07   See Pricing
Sacubitril Argentina 093559 2032-11-20   See Pricing
Sacubitril China 105007928 2032-11-20   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.